This study is testing a drug called HS-20110 in people with advanced solid tumors. HS-20110 is an antibody-drug conjugate, which means it's designed to deliver a drug directly to cancer cells. The main goals are to find the safest dose of HS-20110 and see how well it shrinks tumors. You may be able to join if you are 18 or older and have advanced solid tumors that have been confirmed by a doctor. The study is open-label, meaning both you and your doctors will know you are receiving HS-20110. The study plans to enroll 475 participants.

Study design

This is an open-label study, meaning everyone knows what treatment is being given. It plans to enroll 475 participants with advanced solid tumors.

What's involved

HS-20110 will be given through an IV infusion in 21-day cycles. The study will explore different doses of the drug.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from the first day of treatment until one month after your last dose. Tumor response will be measured from screening until two months after your last dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.